| Business Summary | | Eli
Lilly
and
Company
discovers,
develops,
manufactures
and
sells
products
in
one
significant
business
segment,
called
Pharmaceutical
Products.
The
Company
also
manufactures
and
sells
animal
health
products,
and
manufactures
and
distributes
its
products
through
owned
or
leased
facilities
in
the
United
States,
Puerto
Rico
and
30
other
countries.
The
Company's
products
are
sold
in
approximately
160
countries.
Eli
Lilly
directs
its
research
efforts
primarily
toward
the
search
for
products
to
diagnose,
prevent
and
treat
human
diseases.
The
Company
also
conducts
research
to
find
products
to
treat
diseases
in
animals,
and
to
increase
the
efficiency
of
animal
food
production. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Eli
Lilly
and
Co.
is
engaged
in
the
discovery,
development,
manufacture
and
sale
of
pharmaceutical
products.
For
the
six
months
ended
6/30/01,
net
sales
rose
15%
to
$5.84
billion.
Net
income
rose
8%
to
$1.63
billion.
Revenues
reflect
increased
sales
of
Zyprexa,
Gemzar,
Evista
and
diabetes
care
products.
Earnings
were
partially
offset
by
the
absence
of
$214
million
in
gains
on
sale
of
the
joint
venture
between
Lilly
and
EDS
to
WebMD. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Sidney Taurel, 52 Chairman,
CEO, Pres | $6.1M | $13M | Charles Golden, 54 CFO,
Exec. VP, Director | 2.4M | -- | August Watanabe, M.D., 59 Exec.
VP- Science and Technology | 2.4M | -- | John Lechleiter, 47 Exec.
VP of Pharmaceutical Products and Corp. Devel. | -- | -- | Gerhard Mayr, 54 Exec.
VP, Pharmaceutical Operations | 2.2M | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|